Sarepta Therapeutics, Inc. (NASDAQ:SRPT) to Post Q3 2024 Earnings of $1.92 Per Share, Leerink Partnrs Forecasts

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Analysts at Leerink Partnrs upped their Q3 2024 EPS estimates for Sarepta Therapeutics in a report issued on Monday, June 24th. Leerink Partnrs analyst J. Schwartz now forecasts that the biotechnology company will post earnings per share of $1.92 for the quarter, up from their prior estimate of $1.32. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $3.71 per share. Leerink Partnrs also issued estimates for Sarepta Therapeutics’ Q4 2024 earnings at $5.44 EPS, FY2024 earnings at $7.65 EPS and FY2025 earnings at $11.90 EPS.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.84. The company had revenue of $413.50 million during the quarter, compared to the consensus estimate of $375.52 million. Sarepta Therapeutics had a net margin of 1.20% and a return on equity of 2.20%. Sarepta Therapeutics’s revenue was up 63.1% compared to the same quarter last year. During the same period last year, the firm earned ($1.44) earnings per share.

SRPT has been the subject of a number of other research reports. Bank of America raised their price target on shares of Sarepta Therapeutics from $166.00 to $213.00 and gave the stock a “buy” rating in a report on Friday, June 21st. Mizuho raised their target price on shares of Sarepta Therapeutics from $145.00 to $179.00 and gave the stock a “buy” rating in a report on Friday, May 17th. UBS Group raised their target price on shares of Sarepta Therapeutics from $164.00 to $167.00 and gave the stock a “buy” rating in a report on Friday, March 1st. Oppenheimer raised shares of Sarepta Therapeutics from a “market perform” rating to an “outperform” rating and set a $180.00 target price for the company in a report on Tuesday, May 14th. Finally, Cantor Fitzgerald reissued a “neutral” rating and set a $128.00 target price on shares of Sarepta Therapeutics in a report on Friday, June 21st. Five analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Sarepta Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $185.06.

Sarepta Therapeutics Trading Up 0.7 %

NASDAQ SRPT opened at $157.96 on Wednesday. The company has a fifty day simple moving average of $128.90 and a two-hundred day simple moving average of $121.71. The stock has a market cap of $14.93 billion, a P/E ratio of 1,436.00 and a beta of 0.96. Sarepta Therapeutics has a 12-month low of $55.25 and a 12-month high of $173.25. The company has a current ratio of 4.05, a quick ratio of 3.44 and a debt-to-equity ratio of 1.18.

Institutional Investors Weigh In On Sarepta Therapeutics

Large investors have recently added to or reduced their stakes in the business. Mather Group LLC. purchased a new stake in Sarepta Therapeutics during the 1st quarter worth approximately $28,000. Riggs Asset Managment Co. Inc. increased its stake in Sarepta Therapeutics by 125.0% during the 1st quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock worth $29,000 after buying an additional 125 shares during the period. New Covenant Trust Company N.A. purchased a new stake in Sarepta Therapeutics during the 1st quarter worth approximately $32,000. Cary Street Partners Investment Advisory LLC increased its stake in Sarepta Therapeutics by 154.0% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock worth $31,000 after buying an additional 154 shares during the period. Finally, Principal Securities Inc. purchased a new stake in Sarepta Therapeutics during the 4th quarter worth approximately $26,000. 86.68% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, insider Bilal Arif sold 7,859 shares of the business’s stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $163.08, for a total value of $1,281,645.72. Following the transaction, the insider now directly owns 21,261 shares in the company, valued at approximately $3,467,243.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider Bilal Arif sold 7,859 shares of the business’s stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $163.08, for a total value of $1,281,645.72. Following the sale, the insider now directly owns 21,261 shares of the company’s stock, valued at approximately $3,467,243.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Ryan Edward Brown sold 38,957 shares of the business’s stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $161.61, for a total transaction of $6,295,840.77. Following the completion of the sale, the executive vice president now directly owns 17,129 shares in the company, valued at $2,768,217.69. The disclosure for this sale can be found here. Insiders have sold 50,451 shares of company stock worth $8,086,386 in the last ninety days. 7.70% of the stock is owned by insiders.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.